Navigation Links
Unique nerve-stimulation device proves effective against epilepsy
Date:3/18/2009

Epilepsy is a common medical condition characterized by convulsions and short periods of confusion. It affects more than 50 million people worldwide. But intractable epilepsy, which affects more than 1 million Americans and is often resistant to drug treatment and surgery, is arguably worse.

But in a just completed clinical trial, a unique nerve-stimulation treatment for intractable epilepsy reduced the number of seizures by more than 50 percent. In the March edition of the journal Neurology, UCLA neurology professor Christopher M. DeGiorgio and colleagues report the results of the long-term pilot trial, which demonstrated the effectiveness of the new treatment, called trigeminal nerve stimulation (TNS).

The results, though preliminary, are very encouraging, DeGiorgio said. Those participating in the trial for three months saw a 66 percent reduction in the number of seizures, those participating for six months saw a 56 percent reduction and those who completed one year saw a 59 percent reduction in seizures. One of the subjects who participated for a full year had a 90-percent reduction in seizures.

The trigeminal nerve extends into the brain from the face and forehead and is known to play a role in seizure inhibition. The stimulator, about the size of a large cell phone, attaches to a belt or can slip into a pocket. Two wires from the stimulator are passed under the clothing and connected to electrodes attached to the forehead by adhesive. The electrodes, which can be covered by a cap or scarf, transmit an electrical current to the nerve.

"People with intractable epilepsy who have continuing seizures are often drug-resistant," DeGiorgio said. "In addition, anti-seizure drugs can have significant side effects on thinking and alertness."

Epilepsy brain surgery can be very effective, he said, but some patients are not ideal candidates because there is no single focal point in the brain for their seizures.

A larger clinical trial to further test for safety and effectiveness is now underway. The investigators hope that eventually a device can be permanently implanted above the eyebrow that would stimulate the trigeminal nerve and replace the external device.

"TNS is a promising alternative mode of neurostimulation because the trigeminal nerve can be stimulated in minimally invasive fashion," DeGiorgio said. "The major branches of the trigeminal nerve in the face are located close to the surface of the skull; that allows physicians to assess response prior to permanent implantation of a future device.

"For all of these reasons, we need to find non-drug and non-surgical alternatives," he said. "The results of our study are very encouraging and support further investigation into the safety and efficacy of TNS."


'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Unique role for blood formation gene identified
2. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
3. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
4. Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors
5. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
6. Graduates of Unique New Labor/Management Healthcare Workforce Training Program Honored Today in Oakland
7. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
8. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
9. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
10. Franco e Rizzi Offers Low-Cost Weight Loss Surgery (WLS) With Unique Price Guarantee
11. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t ... the next project in the company’s esteemed VISION House demonstration project series. Manifesting the ... the amount of resources they need to live affordably and abundantly without unduly taxing ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... held the much anticipated Regional Primary Care Spring Symposium on April 1, 2017 ... local medical community, offering physicians and healthcare providers an opportunity to learn about ...
(Date:4/21/2017)... ... , ... BrightStar Care Salt Lake City, a home care agency that also ... has appointed Rex Wheeler as its new Director of Business Development. “This partnership helps ... ability to provide quality care to the community,” said Tammara Brown, owner of BrightStar ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod ... , This festival offers entertainment for everyone — from the avid gardener to ... is a very high quality event held in a grand venue, and we are ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, Inc. ... on providing the Urology, Uro/Gyn and Gynecology markets ... Ash Keswani has joined the Company as Senior ... newly created position, Mr. Keswani will report directly ... "Our organization is delighted that Ash ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology: